Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
 
 

 Latest News

 
4/14/2015
ISPOR and Value in Health, journal for research that advance the field of pharmacogenomics and outcomes research, endorse Pharmerit’s academic research on reimbursement in Scotland.
4/10/2015
Type 2 diabetes mellitus is estimated to account for 7–12% of the UK National Health Service expenditure. Economic analysis is critical to ensuring that limited resources are used effectively.
3/9/2015
Analysis demonstrates the sublingual native 5-grass tablet to be cost-effective relative to a mix of subcutaneous allergoid compounds
3/3/2015
Pharmerit Europe has a new management team of Bram Verheggen, Maarten Treur, and Stephanie Stephens. Together they are responsible for all aspects of Pharmerit Europe, but each has their own key focus.
1/6/2015
Pharmerit conducted an analysis to estimate the incremental cost-effectiveness of hexaminolevulinate for patients diagnosed with non-muscle invasive bladder cancer (NMIBC) in Italy
12/15/2014
Despite its rarity, anal cancer places a significant economic burden on the public purse and moreover resource pressures on the national health service.
11/19/2014
We have enjoyed meeting you at the 17th European ISPOR conference in Amsterdam, November 2014. Hand-outs of the poster sessions are available on our ISPOR Amsterdam event page.
10/7/2014
​Meet our team of experts at the ISOQOL 21st Annual Conference in Berlin, 15-18 October, 2014. We invite you to our exhibit, presentations, and workshop.
9/19/2014
On September 18, 2014, Pharmerit and IPAM jointly hosted a successful workshop in Berlin.
6/23/2014
Adalimumab is cost effective in treating Spanish patients with non-radiographic axial spondyloarthritis and elevated CRP and/or positive MRI.
Contact Feel free to contact us if you have any questions